WALTHAM, Mass., Sept. 4, 2024 /PRNewswire/ — Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company’s NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers. The company has in parallel launched the newest version of its home dialysis machine, the NxStage® Versi®HD with GuideMe Software, featuring enhancements designed to simplify treatment, increase ease of learning, and improve user experience. These achievements highlight the efficacy and reliability of the NxStage system in delivering safe, high-quality care to patients in the comfort of their homes.
Between January and April 2024, the number of new HHD patients starting treatment with NxStage in the United States grew by 18% compared to the same period in 2023. For example, April saw 927 new patients initiating HHD therapy in the U.S.
“We are proud to announce these achievements in our Home Therapies division,” said Joseph Turk, Executive Vice President and Global Head of Home Therapies at Fresenius Medical Care. “These accomplishments underscore our relentless commitment to continuous innovations that enable us to improve the lives of patients seeking the safety, convenience, and flexibility of home dialysis.”
Since the FDA clearance in 2023, the newest NxStage HHD System, Versi®HD with GuideMe Software, has garnered significant interest in the United States. Large, mid-sized, and several independent dialysis providers are moving forward with the adoption of Versi®HD with GuideMe Software.
Versi®HD with GuideMe Software’s advanced technology is designed to simplify HHD treatment and improve ease of learning, skill retention, and user experience for patients and care partners. The machine’s pictorial-based guidance was designed to meet diverse patient needs throughout the setup, treatment and troubleshooting, while improving training time and skill retention. It provides graphical walk-through guidance that aims to enhance ease of use and confidence for both patients and nurses. The interface is designed to accommodate a wide variety of learning styles and improve skill retention from initial training, while static picture instructions allow patients to linger and study any step at their own pace.
“The patient training on Versi®HD with GuideMe-Software at our clinic catch on quickly and feel comfortable by the second week of training. Even better, they are able to complete their training seven to 10 days sooner,” said Sandra Flores, Home Therapies Registered Nurse in North Central Oklahoma City.
Currently, NxStage Versi®HD with GuideMe Software is being fully launched in the U.S. with planned global rollouts over the coming years. For more information about Fresenius Medical Care’s Home Therapies, please visit https://www.nxstage.com/hcp/products/nxstage-versihd-with-guideme-software/
© 2024 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, NxStage, and Versi are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners.
About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,757 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 311,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company’s website at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.
Media contact
Emanuela Cariolagian
T +1 213 706 0051
Emanuela.Cariolagian1@freseniusmedicalcare.com
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
SOURCE Fresenius Medical Care Holdings, Inc.
Young Women Activists Launch "What Girls Want," Demand World Leaders Put Girls at the Center…
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may…
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the…
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment…
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (OTC: SMFL) (“Smart for…
SAN FRANCISCO, Sept. 20, 2024 /PRNewswire/ -- The Global Ultrasound Institute (GUSI) is proud to…